Assessing stated preferences for colorectal cancer screening: A critical systematic review of discrete choice experiments

Patient

Volumn 7, Issue 3, 2014, Pages 271-282

  Wortley, S ^a   Wong, G ^a,b,c   Kieu, A ^b   Howard, K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER SCREENING; CHECKLIST; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISCRETE CHOICE EXPERIMENT; HEALTH CARE COST; HUMAN; PATIENT DECISION MAKING; PATIENT PREFERENCE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

CHOICE BEHAVIOR; COLONOSCOPY; COLORECTAL NEOPLASMS; DECISION MAKING; EARLY DETECTION OF CANCER; OCCULT BLOOD; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE;

EID: 84906937620     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-014-0054-3     Document Type: Review

References (53)

1. Australia Institute of Health and Welfare & Australia Government Department of Health and Ageing. National Bowel Cancer Screening Program monitoring report 2008. Cancer Series 44, Cat. No 40. 2008. Canberra, AIHW. Ref Type: Report.
2. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-7. (Pubitemid 29128279)
3. Scholefield JH, Moss S, Sufi F, Mangham CM, Hardcastle JD. Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial. Gut. 2002;50:840-4. (Pubitemid 34539047)
4. Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med. 1993;329:1977-81. (Pubitemid 24015040)
5. Young GP, St John DJ, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol. 2002;97:2499-507.
6. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366-78.
7. Hol L, Van Leerdam ME, Van Ballegooijen M, Van Vuuren AJ, Van Dekken H, Reijerink JC, Van der Togt AC, Habbema JDF, Kuipers EJ. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62-8.
8. Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection - systematic review and meta-analysis. Radiology. 2011;259:393-405.
9. Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover J, Parkin DM, Wardle J, Duffy SW, Cuzick J. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624-33.
10. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012;366:2345-57.
11. Agrez MV, Redman S, Sanson-Fisher R, Hennrikus D. Feasibility of sigmoidoscopic screening for colorectal cancer in the Hunter Region. Aust N Z J Surg. 1990;60:87-92. (Pubitemid 20086651)
12. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahrén C (1994) Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing: results for 68,308 subjects. Scand J Gastroenterol 29:468-473. (Pubitemid 24144518)
13. Wolf RL, Basch CE, Brouse CH, Shmukler C, Shea S. Patient preferences and adherence to colorectal cancer screening in an urban population. Am J Public Health. 2006;96:809-11.
14. Salkeld GP, Solomon MJ, Short L, Ward J. Measuring the importance of attributes that influence consumer attitudes to colorectal cancer screening. ANZ J Surg. 2003;73:128-32. (Pubitemid 36513097)
15. Smith SK, Trevena L, Simpson JM, Barratt A, Nutbeam D, McCaffery KJ. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ. 2010; 341:c5370.
16. von Wagner C, Good A, Smith SG, Wardle J. Responses to procedural information about colorectal cancer screening using faecal occult blood testing: the role of consideration of future consequences. Health Expect. 2012;15:176-86.
17. de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ (GBR). 2012;21:145-72.
18. Phillips KA, Van BS, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis. 2006;3:A75.
19. Marshall D, McGregor SE, Currie G. Measuring preferences for colorectal cancer screening: what are the implications for moving forward? Patient. 2010;3:79-89.
20. Ghanouni A, Smith SG, Halligan S, Plumb A, Boone D, Yao GL, Zhu S, Lilford R, Wardle J, von Wagner C. Public preferences for colorectal cancer screening tests: a review of conjoint analysis studies. Expert Rev Med Devices. 2013;10:489-99.
21. Salkeld G, Solomon M, Short L, Ryan M, Ward JE. Evidence-based consumer choice: a case study in colorectal cancer screening. Aust N Z J Public Health. 2003;27:449-55. (Pubitemid 37038228)
22. Gyrd-Hansen D, Sogaard J. Analysing public preferences for cancer screening programmes. Health Econ (GBR). 2001;10:617-34. (Pubitemid 32998373)
23. Frew E, Wolstenholme JL, Whynes DK. Willingness-to-pay for colorectal cancer screening. Eur J Cancer. 2001;37:1746-51. (Pubitemid 32817048)
24. Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Val Health. 2011;14:403-13.
25. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-9.
26. Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making. Pharmacoeconomics. 2008;26:661-77. (Pubitemid 351989058)
27. Pignone MP, Brenner AT, Hawley S, Sheridan SL, Lewis CL, Jonas DE, Howard K. Conjoint analysis versus rating and ranking for values elicitation and clarification in colorectal cancer screening. J Gen Intern Med. 2012;27:45-50.
28. de Bekker-Grob EW, Hol L, Donkers B, van Dam L, Habbema JD, van Leerdam ME, Kuipers EJ, Essink-Bot ML, Steyerberg EW. Labeled versus unlabeled discrete choice experiments in health economics: an application to colorectal cancer screening. Val Health. 2010;13:315-23.
29. Cheng J, Pullenayegum E, Marshall DA, Marshall JK, Thabane L. An empirical comparison of methods for analyzing correlated data from a discrete choice survey to elicit patient preference for colorectal cancer screening. BMC Med Res Methodol. 2012;12:15.
30. van Dam L, Hol L, de Bekker-Grob EW, Steyerberg EW, Kuipers EJ, Habbema JD, Essink-Bot ML, van Leerdam ME. What determines individuals' preferences for colorectal cancer screening programmes? A discrete choice experiment. Eur J Cancer. 2010;46:150-9.
31. Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Kulin NA. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Val Health. 2007;10:415-30. (Pubitemid 47481113)
32. Howard K, Salkeld G. Does attribute framing in discrete choice experiments influence willingness to pay? Results from a discrete choice experiment in screening for colorectal cancer. Value Health. 2009;12:354-63.
33. Whynes DK, Frew E, Wolstenholme JL. A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. J Health Econ. 2003;22:555-74. (Pubitemid 36802171)
34. Imaeda A, Bender D, Fraenkel L. What is most important to patients when deciding about colorectal screening? J Gen Intern Med. 2010;25:688-93.
35. Hawley ST, Volk RJ, Krishnamurthy P, Jibaja-Weiss M, Vernon SW, Kneuper S. Preferences for colorectal cancer screening among racially/ethnically diverse primary care patients. Med Care. 2008;46(Suppl 1):S10-16.
36. Salkeld G, Ryan M, Short L. The veil of experience: do consumers prefer what they know best? Health Econ (GBR). 2000;9:267-70. (Pubitemid 30248644)
37. Hol L, de Bekker-Grob EW, van Dam L, Donkers B, Kuipers EJ, Habbema JD, Steyerberg EW, van Leerdam ME, Essink-Bot ML. Preferences for colorectal cancer screening strategies: a discrete choice experiment. Br J Cancer. 2010;102:972-80.
38. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van BS, Phillips KA. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ (GBR). 2009;18:1420-39.
39. Nayaradou M, Berchi C, Dejardin O, Launoy G. Eliciting population preferences for mass colorectal cancer screening organization. Med Decis Mak. 2010;30:224-33.
40. Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint analysis applications in health - how are studies being designed and reported? Patient. 2010;3:249-56.
41. Fagerlin A, Pignone M, Abhyankar P, Col N, Feldman-Stewart D, Gavaruzzi T, Kryworuchko J, Levin CA, Pieterse AH, Reyna V. Clarifying values: an updated review. BMC Med Inform Decis Mak. 2013;13:S8.
42. Coulter A, Kryworuchko J, Mullen P, Ng C, Stilwell D, van der Weijden T. Using a systematic development process. In: Volk R, Llewellyn-Thomas H (eds) Update of the international patient decision aids standard (IPDAS), 2012.
43. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Moher D, Rennie D, de Vet HC, Lijmer JG. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med. 2003;138:W1-12.
44. Brenner A, Howard K, Lewis C, Sheridan S, Crutchfield T, Hawley S, Reuland D, Kistler C, Pignone M. Comparing 3 values clarification methods for colorectal cancer screening decision-making: a randomized trial in the US and Australia. J Gen Intern Med. 2014;29(3):507-13.
45. Carson RT, Louviere JJ, Anderson DA, Arabie P, Bunch DS, Hensher DA, Johnson RM, Kuhfeld WF, Steinberg D, Swait J. Experimental analysis of choice. Market Lett. 1994;5:351-67.
46. Ratcliffe J, Longworth L. Investigating the structural reliability of a discrete choice experiment within health technology assessment. Int J Technol Assess Health Care. 2002;18:139-44. (Pubitemid 34408536)
47. Flitcroft KL, Irwig LM, Carter SM, Salkeld GP, Gillespie JA. Colorectal cancer screening: why immunochemical fecal occult blood tests may be the best option. BMC Gastroenterol. 2012;12:183.
48. Gregory TA, Wilson C, Duncan A, Turnbull D, Cole SR, Young G. Demographic, social cognitive and social ecological predictors of intention and participation in screening for colorectal cancer. BMC Public Health. 2011;11:38.
49. Khalid-de Bakker C, Jonkers D, Smits K, Mesters I, Masclee A, Stockbrügger R. Participation in colorectal cancer screening trials after first-time invitation: a systematic review. Endoscopy. 2011;43:1059-86.
50. Lin OS, Kozarek RA, Gluck M, Jiranek GC, Koch J, Kowdley KV, Irani S, Nguyen M, Dominitz JA. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies. J Gen Intern Med. 2012;27:1349-60.
51. van Dam L, Kuipers EJ, Steyerberg EW, van Leerdam ME, de Beaufort ID. The price of autonomy: should we offer individuals a choice of colorectal cancer screening strategies? Lancet Oncol. 2013;14:e38-46.
52. Taupin DR, Corbett M. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Med J Aust. 2006;184:546-50.
53. Courtney RJ, Paul CL, Sanson-Fisher RW, Carey ML, Macrae FA, Yoong SL. Community approaches to increasing colorectal screening uptake: a review of the methodological quality and strength of current evidence. The Cancer Council Australia; 2012, p. 27-35.